Recent changes
Track the most recent changes to the wiki on this page.
26 April 2018
| m 08:44 | Non-small cell lung cancer, ROS1-positive (2 changes | history) . . (+1,571) . . [Jwarner (2×)] | |
| m | 08:44 (cur | prev) . . (+64) . . Jwarner (talk | contribs) (→Investigational agents) | |
| m | 08:41 (cur | prev) . . (+1,507) . . Jwarner (talk | contribs) (→Crizotinib monotherapy {{#subobject:be5391|Regimen=1}}) |
| m 08:32 | Crizotinib (Xalkori) (diff | hist) . . (+15) . . Jwarner (talk | contribs) |
| m 08:15 | Cabozantinib (Cometriq) (diff | hist) . . (+29) . . Jwarner (talk | contribs) (→References) |
| m 08:14 | Ensartinib (X-396) (diff | hist) . . (+726) . . Jwarner (talk | contribs) |
| N 08:06 | Entrectinib (RXDX-101) (diff | hist) . . (+2,406) . . Jwarner (talk | contribs) (Created page with "==General information== Class/mechanism, from the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/entrectinib NCI Drug Dictionary]: An orally bioavailable in...") |
| m 08:00 | Drug index (diff | hist) . . (+53) . . Jwarner (talk | contribs) (→E) |
| N 07:58 | Lorlatinib (PF-06463922) (diff | hist) . . (+2,285) . . Jwarner (talk | contribs) (Created page with "==General information== Class/mechanism, from the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lorlatinib NCI Drug Dictionary]: An orally available, ATP-c...") |
25 April 2018
| m 17:13 | Acute myeloid leukemia (diff | hist) . . (+29) . . Jwarner (talk | contribs) |
| m 15:15 | Fostamatinib (Tavalisse) (diff | hist) . . (+46) . . Jwarner (talk | contribs) |
| m 14:35 | Levels of Evidence (2 changes | history) . . (-465) . . [Jwarner (2×)] | |
| m | 14:35 (cur | prev) . . (+17) . . Jwarner (talk | contribs) (→Non-comparative efficacy) | |
| m | 14:32 (cur | prev) . . (-482) . . Jwarner (talk | contribs) (→Non-comparative efficacy) |
| m 12:07 | Diffuse large B-cell lymphoma (diff | hist) . . (+60) . . Jwarner (talk | contribs) (→Lenalidomide monotherapy {{#subobject:f5ca0d|Regimen=1}}) |
| m 07:13 | Autologous HSCT (diff | hist) . . (+53) . . Jwarner (talk | contribs) |
| m 07:11 | Hodgkin lymphoma (diff | hist) . . (0) . . Jwarner (talk | contribs) (→References) |
24 April 2018
| m 22:29 | Mantle cell lymphoma (2 changes | history) . . (+1,611) . . [Jwarner (2×)] | |
| m | 22:29 (cur | prev) . . (+777) . . Jwarner (talk | contribs) (→Temsirolimus monotherapy {{#subobject:575bde|Regimen=1}}) | |
| m | 22:27 (cur | prev) . . (+834) . . Jwarner (talk | contribs) (→Ibrutinib monotherapy {{#subobject:1e0d5c|Regimen=1}}) |
| 22:20 | Diffuse large B-cell lymphoma (5 changes | history) . . (+11,543) . . [Jwarner (5×)] | |
| 22:20 (cur | prev) . . (+1,648) . . Jwarner (talk | contribs) (→Pixantrone monotherapy {{#subobject:bedd78|Regimen=1}}) | ||
| 22:17 (cur | prev) . . (+4,109) . . Jwarner (talk | contribs) (→Everolimus monotherapy {{#subobject:fb3cbd|Regimen=1}}) | ||
| m | 22:11 (cur | prev) . . (+2,040) . . Jwarner (talk | contribs) (→Gemcitabine monotherapy {{#subobject:df3421|Regimen=1}}) | |
| m | 22:05 (cur | prev) . . (+1,578) . . Jwarner (talk | contribs) (→Oxaliplatin monotherapy {{#subobject:308526|Regimen=1}}) | |
| m | 21:56 (cur | prev) . . (+2,168) . . Jwarner (talk | contribs) (→Lenalidomide monotherapy {{#subobject:f5ca0d|Regimen=1}}) |
| m 18:06 | Stem cell mobilization (diff | hist) . . (+22) . . Jwarner (talk | contribs) (→Stem cell mobilization) |
| m 18:01 | Allogeneic HSCT (diff | hist) . . (+49) . . Jwarner (talk | contribs) |
| m 17:59 | Venous thromboembolism (VTE) (diff | hist) . . (+22) . . Jwarner (talk | contribs) (→VTE treatment) |
| m 17:58 | Inherited coagulopathy (diff | hist) . . (+22) . . Jwarner (talk | contribs) (→Factor VIII deficiency (Hemophilia A), with inhibitors) |
| m 16:40 | Esophageal cancer (2 changes | history) . . (+42) . . [Jwarner (2×)] | |
| m | 16:40 (cur | prev) . . (+1,978) . . Jwarner (talk | contribs) (→Paclitaxel monotherapy {{#subobject:ed008a|Regimen=1}}) | |
| m | 16:39 (cur | prev) . . (-1,936) . . Jwarner (talk | contribs) (→Ramucirumab & Paclitaxel {{#subobject:fdd93f|Regimen=1}}) |
| m 16:38 | Gastric cancer (2 changes | history) . . (-15) . . [Jwarner (2×)] | |
| m | 16:38 (cur | prev) . . (+2,016) . . Jwarner (talk | contribs) (→Paclitaxel monotherapy {{#subobject:2dcad9|Regimen=1}}) | |
| m | 16:37 (cur | prev) . . (-2,031) . . Jwarner (talk | contribs) (→Ramucirumab & Paclitaxel {{#subobject:fdd93f|Regimen=1}}) |
| m 16:36 | Cervical cancer (diff | hist) . . (-174) . . Jwarner (talk | contribs) |
| m 13:32 | Non-small cell lung cancer (5 changes | history) . . (+4,664) . . [Jwarner (5×)] | |
| m | 13:32 (cur | prev) . . (+110) . . Jwarner (talk | contribs) (→Preceding treatment) | |
| m | 13:31 (cur | prev) . . (+24) . . Jwarner (talk | contribs) (→Carboplatin, Pemetrexed, Bevacizumab {{#subobject:a4bca7|Regimen=1}}) | |
| m | 13:30 (cur | prev) . . (+11) . . Jwarner (talk | contribs) (→Cisplatin, Pemetrexed, Bevacizumab {{#subobject:836c3d|Regimen=1}}) | |
| m | 13:28 (cur | prev) . . (+722) . . Jwarner (talk | contribs) (→Pemetrexed & Bevacizumab {{#subobject:db5671|Regimen=1}}) | |
| m | 13:26 (cur | prev) . . (+3,797) . . Jwarner (talk | contribs) (→Advanced or metastatic disease, first-line, elderly or poor performance status) |
| m 13:09 | Talk:Non-small cell lung cancer (diff | hist) . . (+512) . . Jwarner (talk | contribs) (→April 2018) |
| 09:58 | (User creation log) . . User account Cdougherty (talk | contribs) was created |
23 April 2018
| m 16:38 | Acute myeloid leukemia, IDH-mutated (diff | hist) . . (+196) . . Jwarner (talk | contribs) (→Enasidenib monotherapy {{#subobject:226cb2|Regimen=1}}) |
| m 16:36 | Enasidenib (Idhifa) (2 changes | history) . . (+151) . . [Jwarner (2×)] | |
| m | 16:36 (cur | prev) . . (+14) . . Jwarner (talk | contribs) | |
| m | 16:36 (cur | prev) . . (+137) . . Jwarner (talk | contribs) |
| 12:27 | (User creation log) . . User account Fvrayner (talk | contribs) was created |
| m 11:52 | Breast cancer (diff | hist) . . (+616) . . Jwarner (talk | contribs) (→Neoadjuvant response criteria) |
| m 08:34 | Non-small cell lung cancer, EGFR-mutated (2 changes | history) . . (+258) . . [Jwarner (2×)] | |
| m | 08:34 (cur | prev) . . (+128) . . Jwarner (talk | contribs) (→Osimertinib monotherapy {{#subobject:PYR2|Regimen=1}}) | |
| m | 08:33 (cur | prev) . . (+130) . . Jwarner (talk | contribs) (→Osimertinib monotherapy {{#subobject:e73636|Regimen=1}}) |
22 April 2018
| m 22:46 | Pancreatic cancer (2 changes | history) . . (+1,826) . . [Jwarner (2×)] | |
| m | 22:46 (cur | prev) . . (+840) . . Jwarner (talk | contribs) (→Erlotinib & Gemcitabine {{#subobject:6d97a7|Regimen=1}}) | |
| m | 22:39 (cur | prev) . . (+986) . . Jwarner (talk | contribs) (→Erlotinib & Gemcitabine {{#subobject:bf797a|Regimen=1}}) |
| m 22:27 | Non-small cell lung cancer, EGFR-mutated (diff | hist) . . (-2,990) . . Jwarner (talk | contribs) (→Erlotinib monotherapy {{#subobject:c3c726|Regimen=1}}) |
| m 20:47 | Editing test page (diff | hist) . . (+13,239) . . Jwarner (talk | contribs) |
| m 20:26 | Ovarian cancer (diff | hist) . . (+645) . . Jwarner (talk | contribs) (→Placebo) |
